Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
10,829.3588.0
Stock Analysis, IPO, Mutual Funds, Bonds & More

USFDA completes inspection of Strides Pharma Bengaluru plant

The company's facility in Bengaluru underwent a United States Food and Drug Administration (USFDA) inspection that ended on May 24, 2019, Strides Pharma Science said in a statement.

PTI|
Jul 20, 2019, 05.44 PM IST
0Comments
New Delhi: Drug firm Strides Pharma Science said Saturday the inspection of its formulation facility in Bengaluru by the US health regulator has completed successfully with a voluntary action indicated (VAI) classification. The company's facility in Bengaluru underwent a United States Food and Drug Administration (USFDA) inspection that ended on May 24, 2019, Strides Pharma Science said in a statement.

The Bengaluru facility is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids, Strides Pharma said.

The facility services key regulated markets of the US, Europe, and Australia, it added.
0Comments
Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service